Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback